A detailed history of Cribstone Capital Management, LLC transactions in Amgen Inc stock. As of the latest transaction made, Cribstone Capital Management, LLC holds 109 shares of AMGN stock, worth $32,103. This represents 0.02% of its overall portfolio holdings.

Number of Shares
109
Previous 109 -0.0%
Holding current value
$32,103
Previous $25,000 12.0%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

BUY
$230.71 - $256.74 $922 - $1,026
4 Added 3.81%
109 $27,000
Q1 2022

May 16, 2022

SELL
$219.27 - $242.57 $4,604 - $5,093
-21 Reduced 16.67%
105 $25,000
Q3 2021

Nov 18, 2021

BUY
$212.27 - $248.7 $1,061 - $1,243
5 Added 4.13%
126 $27,000
Q1 2021

Apr 23, 2021

SELL
$221.91 - $258.6 $7,766 - $9,051
-35 Reduced 22.44%
121 $30,000
Q3 2020

Nov 17, 2020

SELL
$234.65 - $260.95 $3,519 - $3,914
-15 Reduced 8.77%
156 $40,000
Q2 2020

Aug 03, 2020

BUY
$197.81 - $242.74 $2,967 - $3,641
15 Added 9.62%
171 $40,000
Q1 2020

Apr 21, 2020

SELL
$182.24 - $241.7 $16,766 - $22,236
-92 Reduced 37.1%
156 $32,000
Q4 2019

Jan 08, 2020

SELL
$189.21 - $243.2 $148,719 - $191,155
-786 Reduced 76.02%
248 $60,000
Q3 2019

Nov 20, 2019

SELL
$174.11 - $208.62 $28,728 - $34,422
-165 Reduced 13.76%
1,034 $200,000
Q2 2019

Jul 22, 2019

BUY
$166.7 - $195.41 $1,833 - $2,149
11 Added 0.93%
1,199 $221,000
Q1 2019

Apr 11, 2019

SELL
$180.87 - $203.88 $4,883 - $5,504
-27 Reduced 2.22%
1,188 $226,000
Q3 2018

Oct 25, 2018

BUY
$185.29 - $208.89 $9,449 - $10,653
51 Added 4.38%
1,215 $252,000
Q2 2018

Jul 24, 2018

BUY
$166.05 - $186.51 $1,992 - $2,238
12 Added 1.04%
1,164 $215,000
Q1 2018

Apr 19, 2018

BUY
$169.43 - $198.0 $13,893 - $16,236
82 Added 7.66%
1,152 $196,000
Q3 2017

Oct 30, 2017

BUY
$167.29 - $191.0 $179,000 - $204,370
1,070
1,070 $200,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Cribstone Capital Management, LLC Portfolio

Follow Cribstone Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cribstone Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cribstone Capital Management, LLC with notifications on news.